TY - JOUR
T1 - Exploiting the burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery/design in structural vaccinology
AU - Gourlay, Louise J.
AU - Peri, Claudio
AU - Ferrer-Navarro, Mario
AU - Conchillo-Solé, Oscar
AU - Gori, Alessandro
AU - Rinchai, Darawan
AU - Thomas, Rachael J.
AU - Champion, Olivia L.
AU - Michell, Stephen L.
AU - Kewcharoenwong, Chidchamai
AU - Nithichanon, Arnone
AU - Lassaux, Patricia
AU - Perletti, Lucia
AU - Longhi, Renato
AU - Lertmemongkolchai, Ganjana
AU - Titball, Richard W.
AU - Daura, Xavier
AU - Colombo, Giorgio
AU - Bolognesi, Martino
PY - 2013/9/19
Y1 - 2013/9/19
N2 - Summary We solved the crystal structure of Burkholderia pseudomallei acute phase antigen BPSL2765 in the context of a structural vaccinology study, in the area of melioidosis vaccine development. Based on the structure, we applied a recently developed method for epitope design that combines computational epitope predictions with in vitro mapping experiments and successfully identified a consensus sequence within the antigen that, when engineered as a synthetic peptide, was selectively immunorecognized to the same extent as the recombinant protein in sera from melioidosis-affected subjects. Antibodies raised against the consensus peptide were successfully tested in opsonization bacterial killing experiments and antibody-dependent agglutination tests of B. pseudomallei. Our strategy represents a step in the development of immunodiagnostics, in the production of specific antibodies and in the optimization of antigens for vaccine development, starting from structural and physicochemical principles. © 2013 Elsevier Ltd.
AB - Summary We solved the crystal structure of Burkholderia pseudomallei acute phase antigen BPSL2765 in the context of a structural vaccinology study, in the area of melioidosis vaccine development. Based on the structure, we applied a recently developed method for epitope design that combines computational epitope predictions with in vitro mapping experiments and successfully identified a consensus sequence within the antigen that, when engineered as a synthetic peptide, was selectively immunorecognized to the same extent as the recombinant protein in sera from melioidosis-affected subjects. Antibodies raised against the consensus peptide were successfully tested in opsonization bacterial killing experiments and antibody-dependent agglutination tests of B. pseudomallei. Our strategy represents a step in the development of immunodiagnostics, in the production of specific antibodies and in the optimization of antigens for vaccine development, starting from structural and physicochemical principles. © 2013 Elsevier Ltd.
U2 - 10.1016/j.chembiol.2013.07.010
DO - 10.1016/j.chembiol.2013.07.010
M3 - Article
SN - 1074-5521
VL - 20
SP - 1147
EP - 1156
JO - Chemistry and Biology
JF - Chemistry and Biology
ER -